Pharmacologic inhibition of SphK2 reduces tumor growth in pre-clinical models for breast, prostate, colon, and hepatocellular cancers [17], [31]–[34], as well as KSHV-associated PEL [18]. Here, SPHK2 is linked to primary effusion lymphoma.